Condition: Rheumatoid Arthritis (RA) · Psoriatic Arthritis (PsA) · Sponsor: LAPIX Therapeutics Inc.
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.
This description comes directly from the study's public registry record.
Anas M Fathallah, PhD · 6172035516 · anas.fathallah@lapixtherapeutics.com
Nimita Dave, PhD · 5139071470 · nimita.dave@lapixtherapeutics.com
Always discuss trial participation with your own doctor first.
| Triumpharma Clinical Research Unit at AlEssra Hospital | Amman, Jordan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06628206